Worse prognosis of real-world patients with acute heart failure
from the Czech AHEAD registry in comparison to patients from
the RELAX-AHF trial

J 2017

Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial

ŠPINAR, Jindřich; Jiří JARKOVSKÝ; Lenka ŠPINAROVÁ; Jiří VÍTOVEC; Ales LINHART et. al.

Základní údaje

Originální název

Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial

Autoři

Vydání

ESC Heart Failure, San Francisco, Wiley Periodicals, 2017, 2055-5822

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00096071

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/ehf2.12105

UT WoS

000397197700002

EID Scopus

2-s2.0-85027555984

Klíčová slova anglicky

Acute heart failure; Mortality; Blood pressure; Vasodilator therapy; AHEAD registry

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 5. 2018 15:35, Soňa Böhmová

Anotace

V originále

The randomized clinical trial RELAX-AHF demonstrated a positive effect of vasodilator therapy with serelaxin in the treatment of AHF patients. The aim of our study was to compare clinical characteristics and outcomes of patients from the AHEAD registry who met criteria of the RELAX-AHF trial (relax-comparable group) with the same characteristics and outcomes of patients from the AHEAD registry who did not meet those criteria (relax-non-comparable group), and finally with characteristics and outcomes of patients from the RELAX-AHF trial. Methods and results A total of 5856 patients from the AHEAD registry (Czech registry of AHF) were divided into two groups according to RELAX-AHF criteria: relax-comparable (n = 1361) and relax-non-comparable (n = 4495). As compared with the relax-non-comparable group, patients in the relax-comparable group were older, had higher levels of systolic and diastolic blood pressure, lower creatinine clearance, and a higher number of comorbidities. Relax-comparable patients also had significantly lower short-term as well as long-term mortality rates in comparison to relax-non-comparable patients, but a significantly higher mortality rate in comparison to the placebo group of patients from the RELAX-AHF trial. Using AHEAD score, we have identified higher-risk patients from relax-comparable group who might potentially benefit from new therapeutic approaches in the future. Conclusions Only about one in five of all evaluated patients met criteria for the potential treatment with the new vasodilator serelaxin. AHF patients from the real clinical practice had a higher mortality when compared with patients from the randomized clinical trial.

Návaznosti

MUNI/A/1362/2015, interní kód MU

Název: Neurohumorální profil a prognóza pacientů s chronickým srdečním selháním

Investor: Masarykova univerzita, Neurohumorální profil a prognóza pacientů s chronickým srdečním selháním, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

ŠPINAR, Jindřich; Jiří JARKOVSKÝ; Lenka ŠPINAROVÁ; Jiří VÍTOVEC; Ales LINHART; Petr WIDIMSKY; Roman MIKLÍK; Kamil ZEMAN; Jan BELOHLAVEK; Filip MALEK; Cestmir CIHALIK; Jiří ŠPÁC; Marián FELŠŐCI; Petr OSTADAL; Ladislav DUŠEK; Jiri KETTNER; Jan VACLAVIK; Simona LITTNEROVÁ; Zdeněk MONHART; Josef MALEK a Jiří PAŘENICA. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. ESC Heart Failure. San Francisco: Wiley Periodicals, 2017, roč. 4, č. 1, s. 8-15. ISSN 2055-5822. Dostupné z: https://doi.org/10.1002/ehf2.12105.

@article{1369974,
   author = {Špinar, Jindřich and Jarkovský, Jiří and Špinarová, Lenka and Vítovec, Jiří and Linhart, Ales and Widimsky, Petr and Miklík, Roman and Zeman, Kamil and Belohlavek, Jan and Malek, Filip and Cihalik, Cestmir and Špác, Jiří and Felšőci, Marián and Ostadal, Petr and Dušek, Ladislav and Kettner, Jiri and Vaclavik, Jan and Littnerová, Simona and Monhart, Zdeněk and Malek, Josef and Pařenica, Jiří},
   article_location = {San Francisco},
   article_number = {1},
   doi = {https://doi.org/10.1002/ehf2.12105},
   keywords = {Acute heart failure; Mortality; Blood pressure; Vasodilator therapy; AHEAD registry},
   language = {eng},
   issn = {2055-5822},
   journal = {ESC Heart Failure},
   title = {Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial},
   volume = {4},
   year = {2017}
}

TY  - JOUR
ID  - 1369974
AU  - Špinar, Jindřich - Jarkovský, Jiří - Špinarová, Lenka - Vítovec, Jiří - Linhart, Ales - Widimsky, Petr - Miklík, Roman - Zeman, Kamil - Belohlavek, Jan - Malek, Filip - Cihalik, Cestmir - Špác, Jiří - Felšőci, Marián - Ostadal, Petr - Dušek, Ladislav - Kettner, Jiri - Vaclavik, Jan - Littnerová, Simona - Monhart, Zdeněk - Malek, Josef - Pařenica, Jiří
PY  - 2017
TI  - Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial
JF  - ESC Heart Failure
VL  - 4
IS  - 1
SP  - 8-15
EP  - 8-15
PB  - Wiley Periodicals
SN  - 20555822
KW  - Acute heart failure
KW  - Mortality
KW  - Blood pressure
KW  - Vasodilator therapy
KW  - AHEAD registry
N2  - The randomized clinical trial RELAX-AHF demonstrated a positive effect of vasodilator therapy with serelaxin in the treatment of AHF patients. The aim of our study was to compare clinical characteristics and outcomes of patients from the AHEAD registry who met criteria of the RELAX-AHF trial (relax-comparable group) with the same characteristics and outcomes of patients from the AHEAD registry who did not meet those criteria (relax-non-comparable group), and finally with characteristics and outcomes of patients from the RELAX-AHF trial. Methods and results A total of 5856 patients from the AHEAD registry (Czech registry of AHF) were divided into two groups according to RELAX-AHF criteria: relax-comparable (n = 1361) and relax-non-comparable (n = 4495). As compared with the relax-non-comparable group, patients in the relax-comparable group were older, had higher levels of systolic and diastolic blood pressure, lower creatinine clearance, and a higher number of comorbidities. Relax-comparable patients also had significantly lower short-term as well as long-term mortality rates in comparison to relax-non-comparable patients, but a significantly higher mortality rate in comparison to the placebo group of patients from the RELAX-AHF trial. Using AHEAD score, we have identified higher-risk patients from relax-comparable group who might potentially benefit from new therapeutic approaches in the future. Conclusions Only about one in five of all evaluated patients met criteria for the potential treatment with the new vasodilator serelaxin. AHF patients from the real clinical practice had a higher mortality when compared with patients from the randomized clinical trial.
ER  -

ŠPINAR, Jindřich; Jiří JARKOVSKÝ; Lenka ŠPINAROVÁ; Jiří VÍTOVEC; Ales LINHART; Petr WIDIMSKY; Roman MIKLÍK; Kamil ZEMAN; Jan BELOHLAVEK; Filip MALEK; Cestmir CIHALIK; Jiří ŠPÁC; Marián FELŠ$\backslash$H OCI; Petr OSTADAL; Ladislav DUŠEK; Jiri KETTNER; Jan VACLAVIK; Simona LITTNEROVÁ; Zdeněk MONHART; Josef MALEK a Jiří PAŘENICA. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. \textit{ESC Heart Failure}. San Francisco: Wiley Periodicals, 2017, roč.~4, č.~1, s.~8-15. ISSN~2055-5822. Dostupné z: https://doi.org/10.1002/ehf2.12105.

Přehled o publikaci